EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia

Mirjana Suver Stević iD, Vlatka Periša iD, Karla Vujičić, Saška Marczi, Jasminka Sinčić-Petričević, Danijela Mjeda

Diagnostics · 15.07.2026 · 16 (14) · 2216

DOI: 10.3390/diagnostics16142216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 15.07.2026. Verfasst von Mirjana Suver Stević und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Quantitative PCR measurement of BCR::ABL1 is essential for monitoring molecular response and detecting relapse in chronic myeloid leukemia (CML) patients. Given the availability of multiple commercial kits for cDNA synthesis and minimal residual disease assessment, analytical accuracy and reliability are critical. This study evaluated two commercial RT and qPCR kits for BCR::ABL1 quantification and fusion transcript variant identification.

Methods

Total RNA was isolated from peripheral blood, bone marrow, and external quality control samples from the UK NEQAS for Leucocyte Immunophenotyping program. cDNA synthesis was performed using two kits: AffinityScript (ASK) and RT Kit (RTK). BCR::ABL1 transcript levels were determined using the ipsogen® BCR-ABL1 Mbcr IS-MMR Kit (IPS) and the LightMix® bcr-abl t(9;22) M/m/µ Kit (TMB). Results were compared with UK NEQAS LI reference data. Fusion transcript variants were analyzed using nested PCR and a commercial qPCR assay.

Results

Substantial variability was observed between the TMB and IPS assays, with moderate, non-significant correlation and wide limits of agreement. Established discrepancies resulted in different classifications of molecular response, and IPS results showed better concordance with external quality assessment data. ABL1 quantification revealed significantly higher copy numbers with the RTK compared to the ASK (p < 0.0001), enabling more reliable assessment of deep molecular responses. Statistical analyses indicated systematic and proportional bias between the methods. For variant detection, nested PCR demonstrated higher specificity, while the commercial assay showed limited discriminatory capability.

Conclusions

Significant methodological differences may affect clinical interpretation, underscoring the importance of validation and standardization in CML molecular monitoring.

Schlagwörter

Stichwörter der Autor:innen

BCR-ABL positivechroniclaboratory proficiency testingleukemiamyelogenousquantitative polymerase chain reactionreverse transcriptase polymerase chain reaction

Autor:innen und Institutionen

  • University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia.
  • Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia.
  • Department of Biology, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia.

ORCID-Profile: Mirjana Suver Stević, Vlatka Periša

Zitieren

APA

Suver Stević, M., Periša, V., Vujičić, K., Marczi, S., Sinčić-Petričević, J., & Mjeda, D. (2026). One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia. Diagnostics, 16(14), 2216. https://doi.org/10.3390/diagnostics16142216

Vancouver

Suver Stević M, Periša V, Vujičić K, Marczi S, Sinčić-Petričević J, Mjeda D. One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia. Diagnostics. 2026;16(14):2216. doi:10.3390/diagnostics16142216

BibTeX
@article{SuverStevi2026,
  author = {Suver Stević, Mirjana and Periša, Vlatka and Vujičić, Karla and Marczi, Saška and Sinčić-Petričević, Jasminka and Mjeda, Danijela},
  title = {One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {14},
  pages = {2216},
  doi = {10.3390/diagnostics16142216}
}
Kostenlos starten →